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Efficacy and safety profile of mucolytic/
antioxidant agents in chronic obstructive
pulmonary disease: a comparative analysis
across erdosteine, carbocysteine, and N-
acetylcysteine
Paola Rogliani1* , Maria Gabriella Matera2, Clive Page3, Ermanno Puxeddu1, Mario Cazzola1 and Luigino Calzetta1
Abstract
Background: To date there are no head-to-head studies comparing different mucolytic/antioxidant agents. Considering
the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive
pulmonary disease (COPD), and the recent publication of Reducing Exacerbations and Symptoms by Treatment with ORal
Erdosteine in COPD (RESTORE) study, we have performed a meta-analysis to compare the efficacy and safety of
erdosteine 600mg/day, carbocysteine 1500mg/day, and N-acetylcysteine (NAC) 1200mg/day in COPD.
Methods: A pairwise and network meta-analyses were performed to assess the efficacy of erdosteine, carbocysteine, and
NAC on acute exacerbation of COPD (AECOPD), duration of AECOPD, and hospitalization. The frequency of adverse
events (AEs) was also investigated.
Results: Data obtained from 2753 COPD patients were extracted from 7 RCTs published between 2004 and 2017. In the
pairwise meta-analysis mucolytic/antioxidant agents significantly reduced the risk of AECOPD (RR 0.74 95%CI 0.68–0.80).
The network meta-analysis provided the following rank of effectiveness: erdosteine>carbocysteine>NAC. Only erdosteine
reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05).
Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01). The AEs induced by erdosteine,
carbocysteine, and NAC were mild in severity and generally well tolerated. The quality of evidence of this quantitative
synthesis is moderate.
Conclusions: The overall efficacy/safety profile of erdosteine is superior to that of both carbocysteine and NAC. Future
head-to-head studies performed on the same COPD populations are needed to definitely confirm the results of this
meta-analysis.
Trial registration: CRD42016053762.
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Background
The regular treatment with mucolytic/antioxidant agents
such as erdosteine, carbocysteine, and N-acetylcysteine
(NAC) is recommended in patients with chronic ob-
structive pulmonary disease (COPD) [1]. In fact, the last
Global Initiative for Chronic Obstructive Lung Disease
(GOLD, 2019) document indicates that mucolytic/anti-
oxidant drugs may reduce the risk of acute exacerbation
of COPD (AECOP) and improve health status [1].
Until 2015 there was no evidence to precisely identify
the target population for mucolytic/antioxidant agents in
COPD [2, 3], and a recent not pre-specified post-hoc
analysis PANTHEON study (Placebo-controlled study
on efficAcy and safety of N-acetylcysTeine High dose in
Exacerbations of chronic Obstructive pulmoNary dis-
ease) provided conflicting evidence concerning the role
of inhaled corticosteroid (ICS) therapy and smoking
habit on the protective effect of high-dose NAC against
the risk of AECOPD [4]. Conversely, a quantitative syn-
thesis of randomized controlled trials (RCTs) performed
in agreement with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) State-
ment demonstrated, via a meta-regression analysis, that
the only factors that could significantly influence the ef-
ficacy of mucolytic/antioxidant agents in COPD were
the quality of RCTs, the duration of treatment, and the
number of AECOPD in the year previous the study en-
rolment [5]. Interestingly, the recent Reducing Exacerba-
tions and Symptoms by Treatment with ORal Erdosteine
in COPD (RESTORE) study [6] showed that erdosteine
was effective in reducing the rate and duration of
AECOPD irrespective of event severity and concomitant
ICS treatment.
To date no head-to-head RCTs across different muco-
lytic/antioxidant agents have been conducted to directly
compare the efficacy profile of erdosteine, carbocysteine,
and NAC. Therefore, in the light of the inconsistent evi-
dence resulting from the pivotal RCTs on mucolytic/anti-
oxidant agents tested in COPD [7–10], and the recent
publication of RESTORE study [6], we have performed a
pairwise and network meta-analysis of the currently avail-
able data aimed to compare the real efficacy of erdosteine,
carbocysteine, and high-dose NAC on AECOPD.
Materials and methods
Search strategy
This meta-analysis has been registered in the international
database of prospectively registered systematic reviews
(PROSPERO registration number: CRD42016053762),
and performed in agreement with the PRISMA-P [11],
with the flow diagram reported in Fig. 1A. This quantita-
tive synthesis satisfied all the recommended items re-
ported by the PRISMA-P checklist [11].
Two reviewers performed a comprehensive literature
search for RCTs evaluating the influence of mucolytic
and antioxidant agents in COPD patients. The PICO
(Patient problem, Intervention, Comparison, and Out-
come) framework was used to develop the literature
search strategy, as previously described [12]. Namely, the
“Patient problem” included subject affected by COPD;
Fig. 1 PRISMA flow diagram for the identification of studies included in the meta-analysis (a) and diagram displaying the network across the
treatments; the links between nodes indicate the direct comparisons between pairs of treatments; the numbers shown along the link lines
indicate the number of patients comparing pairs of treatments head-to-head (b)
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the “Intervention” regarded the administration of muco-
lytic and antioxidant agents; the “Comparison” was per-
formed with regard to placebo and across each active
treatment; the “Outcomes” were the duration of
AECOPD, hospitalizations due to AECOPD, and adverse
events (AEs).
The terms “erdosteine” OR “carbocysteine” OR “NAC”
AND “COPD” AND “clinical trial” were searched in
Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, Scopus, Web of Science,
ClinicalTrials.gov and EU Clinical Trials Register data-
bases in order to provide for relevant studies available
up to November 26, 2018. No language restriction was
applied. The following Query Translation was used:
“((“erdosteine”[Supplementary Concept] OR “erdostei-
ne”[All Fields]) OR (“carbocysteine”[MeSH Terms] OR
“carbocysteine”[All Fields]) OR (“acetylcysteine”[MeSH
Terms] OR “acetylcysteine”[All Fields] OR “n acetylcys-
teine”[All Fields])) AND (“pulmonary disease, chronic
obstructive”[MeSH Terms] OR (“pulmonary”[All Fields]
AND “disease”[All Fields] AND “chronic”[All Fields]
AND “obstructive”[All Fields]) OR “chronic obstructive
pulmonary disease”[All Fields] OR “copd”[All Fields])
AND Clinical Trial[ptyp]”.
Citations of previously published meta-analyses and
relevant reviews were examined to identify further per-
tinent studies, if any [3, 5, 13–15].
Study selection
Published RCTs involving COPD patients treated for
more than 6months with oral formulations of erdosteine
600 mg/day, carbocysteine 1500mg/day, and NAC 1200
mg/day were included in this meta-analysis.
Two reviewers independently checked the relevant
studies identified from literature searches obtained from
the already mentioned databases. The studies were se-
lected in agreement with the above-mentioned criteria,
and any difference in opinion about eligibility was re-
solved by general consensus.
Endpoints
The primary endpoint of this meta-analysis was the im-
pact of erdosteine 600 mg/day, carbocysteine 1500mg/
day, and NAC 1200 mg/day on the reduction in the risk
of AECOPD, compared to placebo and across each ac-
tive treatment.
The secondary endpoints were the impact of erdos-
teine 600 mg/day, carbocysteine 1500mg/day, and NAC
1200 mg/day on the risk of experiencing at least on
AECOPD, the duration of AECOPD, and the risk of
hospitalization due to AECOPD, compared to placebo.
The frequency of AEs was another secondary endpoint.
Quality score, risk of bias and evidence profile
The Jadad score, with a scale of 1 to 5 (score of 5 being
the best quality), was used to assess the quality of the
RCTs concerning the likelihood of biases related to
randomization, double blinding, withdrawals and drop-
outs [16]. A Jadad score ≥ 3 was defined to identify high
quality studies. Two reviewers independently assessed
the quality of individual studies, and any difference in
opinion about the quality score was resolved by
consensus.
In the pairwise meta-analysis moderate to high levels
of heterogeneity between-studies were considered for
I2 > 50%; the risk of publication bias was assessed for
primary endpoints by applying the funnel plot and
Egger’s test, as previously described [16]. Evidence of
asymmetry from Egger’s test was considered to be sig-
nificant at P < 0.1, and the graphical representation of
90% confidence bands have been presented [16]. The
risk of bias in the network meta-analysis was checked
via the consistency/inconsistency analysis to assess
whether the outcomes resulting from the consistency
and inconsistency models fit adequately with the line of
equality, as previously described [5].
The quality of the evidence was assessed for the pri-
mary endpoint in agreement with the Grading of Rec-
ommendations Assessment, Development, and
Evaluation (GRADE) system, indicating ++++ for high
quality of evidence, +++ for moderate quality of evi-
dence, ++ for low quality of evidence, and + for very low
quality of evidence [17].
Data extraction
Data from included RCTs were extracted and checked for
study characteristics and duration, enrolled patients, drugs
and daily doses, disease characteristics, AECOPD defin-
ition, history and rate of AECOPD, age, gender, smoking
habit, lung function, and Jadad score. Due to the complex-
ity of this meta-analysis, data have been extracted in
agreement with DECiMAL recommendations [18].
Data analysis
A pairwise meta-analysis was performed to quantify the
impact of erdosteine 600 mg/day, carbocysteine 1500
mg/day, and NAC 1200 mg/day on primary and second-
ary endpoints, compared to placebo.
The follow-up duration could be not consistent across
the RCTs included in this meta-analysis. Therefore, the
data concerning the risk assessment have been normal-
ized as a function of person-time (namely person-
season), where one season lasts three months [19]. This
method involves the conversion of the measures into a
common metric (events per person-time) prior to meta-
analyze the data, leading to increased estimates of effect,
precision, and clinical interpretability of results [20, 21].
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Specifically, the numerator represents the count of total
events and the denominator represents the given time
duration multiplied by the number of patients [22]. Such
a method has been supported by the Cochrane Collabor-
ation and successfully used in recent meta-analyses [20,
21, 23, 24].
Results of the pairwise meta-analysis are expressed as
relative risk (RR) or mean difference (MD), and 95%
confidence interval (95%CI). Since data were selected
from a series of studies performed by researchers operat-
ing independently, and a common effect size cannot be
assumed, binary random-effects model was used in order
to balance the study weights and adequately estimate the
95%CI of the mean distribution of drugs effect on the in-
vestigated variables [16].
A network meta-analysis was also carried out to per-
form a comparison across the investigated agents with re-
spect to the primary endpoint, and to rank their efficacy
in reducing the risk on AECOPD. The network meta-
analysis was carried out by including exclusively high
quality RCTs that introduced neither heterogeneity nor
bias in the overall effect estimate of primary endpoint.
Since heterogeneity and bias may propagate through a
network of RCTs, and thus affect the estimates differen-
tially across regions of the network, this approach permit-
ted to identify those studies that might alter the correct
results of the network meta-analysis [25].
Full Bayesian evidence network was used was used in
the network meta-analysis (chains: 4; initial values scaling:
2.5; tuning iterations: 20.000; simulation iterations: 50.000;
tuning interval: 10). The convergence diagnostics for
consistency and inconsistency was assessed via the
Brooks-Gelman-Rubin method, as previously described
[26]. Results of the network meta-analysis are expressed
as relative effect (RE) and 95% credible interval (95%CrI).
The probability that each intervention arm was the most
effective was calculated by counting the proportion of iter-
ations of the chain in which each intervention arm had
the highest mean difference, and the surface under the cu-
mulative ranking curve (SUCRA), representing the sum-
mary of these probabilities, was also calculated. The
SUCRA is 1 when a treatment is certain to be the best,
and 0 when a treatment is certain to be the worst [27].
Sensitivity analysis was performed to identify the stud-
ies that introduced heterogeneity and bias in the effect
estimate of primary endpoint.
The analysis of the number needed to treat (NNT)
was performed on primary endpoint. NNT is the recip-
rocal of the absolute risk reduction associated with an
intervention over a fixed period of time [28–30]. The
values of NNT are reported in this study as person-
based and calculated by analyzing the Kaplan-Meier
curves or by using the raw data provided in the primary
publications, as previously described [31, 32]. The
relative weight of each study resulting from the pairwise
meta-analysis was used to calculate the weighted average
rate of the investigated arms and to correctly provide
NNT values.
The safety profile of the investigated treatments was
investigated through a pooled analysis of the frequency
of AEs, which was ranked in agreement with European
Medicine Agency (EMA) guidelines: very common ≥1/
10, common ≥1/100 to < 1/10, uncommon ≥1/1000 to <
1/100, frequency not known if not calculable from the
extracted data.
OpenMetaAnalyst [33] and GeMTC [34] software
were used for performing the meta-analysis, GraphPad
Prism (CA, US) software to graph the data, and GRA-
DEpro GDT to assess the quality of evidence [17]. The
statistical significance for the effect estimates resulting
from the pairwise and network meta-analyses was
assessed for P < 0.05.
Results
Studies characteristics
Results obtained from 2753 COPD patients (11.15%
treated with erdosteine, 18.27% treated with carbocys-
teine, 20.41% treated with NAC, and 50.16% treated with
placebo) were selected from 7 RCTs [6–10, 35, 36] pub-
lished between 2004 and 2017. The relevant characteris-
tics of studies, disease, and patients and the definition of
AECOPD are described in Table 1; Fig. 1B shows the
network across the treatments.
Five RCTs were published as full-text papers [6–10],
and two RCTs as letters to the editor [35, 36]. Six RCTs
were published as high quality studies (Jadad score ≥ 3)
[6–10, 36], and one as low-quality study (Jadad score = 1)
[35]. The duration of treatment ranged from 32weeks to
52 weeks.
Primary endpoint
The pairwise meta-analysis indicated that erdosteine,
carbocysteine, and NAC both significantly reduced the
risk of AECOPD. The overall effect estimate was affected
by high and significant heterogeneity that was driven by
the studies on carbocysteine and NAC. Conversely, the
effect estimate resulting for erdosteine was free from any
heterogeneity (Fig. 2A).
The sensitivity analysis indicated that the main source
of heterogeneity was introduced by the studies of Tat-
sumi et al. and Yasuda et al. on carbocysteine [35, 36], as
excluding these RCTs the overall heterogeneity reduced
at acceptable and not significant levels (I2 26%, P > 0.05)
(Fig. 2B). Nevertheless, the visual inspection of funnel
plot indicated that the study of Tse et al. [8] introduced
a certain level of publication bias (Fig. 2C). In fact
Egger’s test indicated that the results of sensitivity ana-
lysis were affected by significant publication bias, as the
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regression line and 90% confidence bands did not inter-
cept the origin of the graph (Fig. 2D). A further sensitiv-
ity analysis confirmed that the study of Tse et al. [8] was
a source of publication bias, as the regression line and
90% confidence bands of Egger’s test intercepted the ori-
gin of the graph (Y-intercept − 1.64, − 6.23 to 3.00) when
this RCT [8] was removed from the analysis.
The results of the network meta-analysis showed that
there was not significant difference (P > 0.05) across the
investigated drugs with respect to their effect against the
risk of AECOPD (erdosteine vs. carbocysteine: RE 0.97,
95%CrI 0.34–2.56; carbocysteine vs. NAC: RE 0.95,
95%CrI 0.29–2.92; erdosteine vs. NAC: RE 0.92, 95%CrI
0.32–2.38). However, the network meta-analysis indi-
cated that erdosteine was the most effective agent in
preventing the risk of AECOPD (upper quartile in the
SUCRA ranking), followed by carbocysteine and NAC
(third quartile in the SUCRA ranking) (Fig. 2E).
The consistency/inconsistency analysis showed that all
points fit adequately with the line of equality (goodness
of fit: R2 0.99; slope 0.96, 95%CI 0.90–1.02), indicating
that the network meta-analysis was not affected by sig-
nificant bias.
The person-based NNT analysis reported that 10.11
(95%CI 5.41–76.39) patients had to be treated with
erdoisteine for one year to prevent one AECOPD, com-
pared to placebo (P < 0.05). Conversely, the NNT values
for both carbocysteine (30.92, 95%CI 8.61 - ∞) and NAC
(15.69, 95%CI 7.31 - ∞) were not significantly different
(P > 0.05) than placebo.
The GRADE analysis indicated high quality of evi-
dence (++++) for erdosteine, low quality of evidence (+
+) for carbocysteine, and moderate quality of evidence
(+++) for NAC, when compared to placebo. The quality
of evidence in the network meta-analysis comparing
erdosteine, carbocysteine, and NAC via placebo arm was
moderate (+++).
Secondary endpoints
Erdosteine, but neither carbocysteine nor NAC, signifi-
cantly (P < 0.01) reduce the risk of experiencing at least
one AECOPD, compared to placebo (Fig. 3A). Erdos-
teine and NAC both significantly (P < 0.01 and P < 0.001,
respectively) reduced the duration of AECOPD, com-
pared to placebo; no data on this outcome are currently
available for carbocysteine (Fig. 3B). Erdosteine, but not
NAC, significantly (P < 0.05) reduced the risk of
hospitalization due to AECOPD, compared to placebo;
no data on this outcome are currently available for car-
bocysteine (Fig. 3C).
The pooled analysis of safety profile showed that AEs
were very common in patients treated with NAC, and
common in those treated with either erdosteine and car-
bocysteine, or that received placebo. However, AEs were
Fig. 2 Forest plot of pair-wise meta-analysis of primary endpoints: impact of the erdosteine, carbocysteine, and NAC on the risk of AECOPD vs.
placebo (a); sensitivity analysis performed by excluding the studies that introduced significant heterogeneity in the overall effect estimate (b);
publication bias assessment via funnel plot (c) and Egger’s test (d); ranking plot resulting from the network meta-analysis in which treatments were
plotted on X-axis according to SUCRA (score of 1 being the most effective) and on Y-axis according to the rank of being the best treatment (score of 1
being the most effective) (e). #P < 0.1, *P < 0.05, **P < 0.01, and ***P < 0.001. AECOPD acute exacerbation of COPD, COPD chronic obstructive pulmonary
disease, NA not available, NAC N-acetylcysteine, SND standard normal deviate, SUCRA surface under the cumulative ranking curve
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mild in severity and generally well tolerated. The most
frequent AEs was respiratory tract infection (NAC:
10.85%, carbocysteine: 0.56%, erdosteine: not detectable),
and detailed frequencies of further specific AEs are re-
ported in Table 2.
Discussion
In this quantitative synthesis of current literature both
erdosteine, carbocysteine, and NAC fulfilled the primary
endpoint represented by the reduction in the risk of
AECOPD. Considering exclusively the high-quality RCTs
that did not introduce significant heterogeneity in the
pairwise meta-analysis, this study indicates that the mean
effect estimate of the overall impact of mucolytic/antioxi-
dant agents reached the minimal clinically important dif-
ference (MCID: ≈0.75 RR) [19, 38] in reducing the risk of
AECOPD compared to placebo. In any case, the results of
pairwise meta-analysis seem to be affected by a certain
level of publication bias that was mainly related with the
results extracted from the study of Tse et al. [8], as con-
firmed by both funnel plot and Egger’s test analyses.
Although we found no significant difference across the
investigated drugs with respect to their protective effect
against AECOPD, the SUCRA analysis resulting from
the network meta-analysis indicated that erdosteine was
the most effective agent, followed by carbocysteine and
NAC. Interestingly, the consistency/inconsistency ana-
lysis showed that the network meta-analysis was not af-
fected by significant bias.
The superiority of erdosteine with respect to carbocys-
teine and NAC was also confirmed by the NNT analysis,
that provided significant NNT values for erdosteine but
Fig. 3 Forest plot of pair-wise meta-analysis of secondary endpoints: impact of the erdosteine, carbocysteine, and NAC on the risk of
experiencing at least one AECOPD (a), duration of AECOPD (b), and risk of hospitalization due to AECOPD (c), vs. placebo. *P < 0.05 and **P < 0.01.
AECOPD: acute exacerbation of COPD; COPD: chronic obstructive pulmonary disease
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neither for carbocysteine nor for NAC, when compared
to placebo. Specifically, ≈10 patients had to be treated
with erdoisteine for one year to prevent one AECOPD.
The analysis of the quality of evidence concerning the
efficacy on risk of AECOPD compared to placebo indi-
cates that we can be very confident that the true effect
of erdosteine lies close to that of the estimate of the ef-
fect. Conversely, moderate to limited confidence resulted
for NAC and carbocysteine, respectively. This means
that while further research is very unlikely to change our
confidence in the estimate of effect resulting for erdos-
teine, future studies are likely to very likely to have an
important impact on the confidence in the estimate of
effect resulting for NAC and carbocysteine [39]. Due to
the indirect comparison across erdosteine, carbocysteine,
and NAC in the Bayesian process, the quality of evi-
dence of network meta-analysis is moderate, thus repre-
senting the main limitation of our study.
Further limits of this quantitative synthesis are repre-
sented by the difference, or missing data, concerning the
baseline characteristics of COPD patients enrolled in the
RCTs and included in the meta-analysis, namely the
current smoking levels, respiratory function impairment,
and rate of AECOPD in the previous year. Besides, also
the definition of AECOPD was not consistent across the
studies included in this meta-analysis. The risk assess-
ment was normalized as a function of person-time since
the follow-up was not consistent across the RCTs in-
cluded in the meta-analysis. Although this procedure
has been extensively validated and supported by the
Cochrane Collaboration [20, 21], adjusting data for dif-
ferent follow-up duration may represent another minor
limitation of the study.
Concerning the secondary endpoints, only erdosteine
was significantly effective in reducing the risk of experien-
cing at least one AECOPD and the risk of hospitalization
due to AECOPD, whereas the duration of AECOPD was
significantly reduced by both erdosteine and NAC.
The pooled analysis of AEs indicates that the mucolytic/
antioxidant agents investigated in this study are character-
ized by a positive safety profile, and that the recorded AEs
were mild in severity and generally well tolerated.
Indeed the efficacy and safety profile of mucolytic/anti-
oxidant agents resulting by quantitative synthesis of the
current literature supports the use of erdosteine, carbocys-
teine, and NAC in COPD patients, as recommended by
the last (GOLD) document [1]. Considering that most the
pivotal RCTs [6, 7, 9] explored the impact of mucolytic/
antioxidant agents on the rate of overall AECOPD, that
includes both mild, moderate and severe exacerbations, to
date it is still unclear whether these drugs can be effective
in specifically reducing the risk of moderate or severe
AECOPD. Furthermore, considering the moderate quality
of evidence resulting from the network meta-analysis, and
the lack of significant difference across the investigated
drugs, we cannot exclude that future study may change
the rank provided by the SUCRA analysis.
Conclusion
Concluding, the current evidence suggests that the overall
efficacy/safety profile of erdosteine is superior to that of
both carbocysteine and NAC. However, future head-to-
head studies performed on the same COPD populations
are needed to definitely confirm the results of this quanti-
tative synthesis.
Table 2 Pooled analysis of AEs extracted from the studies on erdosteine, carbocysteine, and NAC in COPD patients and ranked by
frequency in agreement with EMA guidelines [37]
Erdosteine Carbocysteine NAC Placebo
Total number of subjects 354 557 553 1151
Frequency (%) of all AEs 1.32 (+++) 2.26 (+++) 18.26 (++++) 8.43 (+++)
Frequency (%) of specific AEs:
respiratory tract infection ND 0.56 (+++) 10.85 (++++) 4.26 (+++)
gastrointestinal disorders 0.44 (++) 1.13 (+++) 4.16 (+++) 4.26 (+++)
pruritus ND ND 1.08 (+++) 2.69 (+++)
cerebrovascular disorders 0.44 (++) ND 0.90 (++) 0.09 (+)
dizziness ND ND 0.72 (++) 0.09 (+)
musculoskeletal disorders ND 0.28 (++) 0.54 (++) 0.78 (++)
hepatobiliary disorders 0.44 (++) ND ND ND
malaise ND 0.28 (++) ND 0.09 (+)
insomnia ND ND ND 0.26 (++)
increased cough ND ND ND 0.17 (++)
++++: very common (≥1/10); +++: common (≥1/100 to < 1/10); ++: uncommon (≥1/1000 to < 1/100); +: rare (≥1/10,000 to < 1/1000); AEs: adverse events; COPD:
chronic obstructive pulmonary disease; EMA: European Medicine Agency; NAC: N-acetylcysteine; ND: not detectable (frequency not known)
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